<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Project 2 – Rational Combination Strategies with TKIs</title>
  <link rel="stylesheet" href="../style.css" />
</head>
<body>
  <header>
    <img src="../images/UB_logo.png" alt="University at Buffalo Logo" class="header-logo" />
    <h1>Roberto Pili Lab at the University at Buffalo</h1>
    <nav>
      <ul>
        <li><a href="../index.html">Overview</a></li>
        <li><a href="../team.html">Team</a></li>
        <li><a href="../projects.html" class="active">Research Projects</a></li>
        <li><a href="../contact.html">Contact</a></li>
      </ul>
    </nav>
  </header>

  <main>
    <section>
      <h2>Developing Rational Combination Strategies with TKIs</h2>
      <p>
        Over the past several years, we have been pursuing preclinical studies aimed at developing combination therapies targeting the tumor vasculature. Among the targets identified for rational combination strategies, we have identified Dll4 and HGF/c-met.
      </p>
      <h3>Key Publications</h3>
      <ul>
        <li>
          Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides B, Qian DZ, Yancopoulos GD, Pili R. 
          <i>Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.</i> 
          Clin Cancer Res. 2007 Jul 15;13(14):4201-8. 
          <a href="https://pubmed.ncbi.nlm.nih.gov/17634549/" target="_blank">PMID: 17634549</a>
        </li>
        <li>
          Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R. 
          <i>Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.</i> 
          Clin Cancer Res. 2008 Jun 1;14(11):3589-97. 
          <a href="https://pubmed.ncbi.nlm.nih.gov/18519793/" target="_blank">PMID: 18519793</a>
        </li>
        <li>
          Ciamporcero E, Miles KM, Adelaiye R, Ramakrishnan S, Shen L, Ku S, Pizzimenti S, Sennino B, Barrera G, Pili R. 
          <i>Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.</i> 
          Mol Cancer Ther. 2015 Jan;14(1):101-10. 
          <a href="https://pubmed.ncbi.nlm.nih.gov/25381264/" target="_blank">PMID: 25381264</a>
        </li>
        <li>
          Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M, Hsu CC, Chintala S, Orillion A, Miles KM, Shen L, Elbanna M, Ciamporcero E, Arisa S, Pettazzoni P, Draetta GF, Seshadri M, Hancock B, Radovich M, Kota J, Buck M, Keilhack H, McCarthy BP, Persohn SA, Territo PR, Zang Y, Irudayaraj J, Tao WA, Hollenhorst P, Pili R. 
          <i>EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.</i> 
          Cancer Res. 2017 Dec 1;77(23):6651-6666. 
          <a href="https://pubmed.ncbi.nlm.nih.gov/28978636/" target="_blank">PMID: 28978636</a>
        </li>
      </ul>
    </section>
  </main>

  <footer>
    <p>© 2025 Roberto Pili Lab | University at Buffalo</p>
  </footer>
</body>
</html>